Metastatic malignant melanoma with an unknown primary.

Area of Science:

• Oncology
• Dermatology
• Surgical Pathology

Background:

• Metastatic melanoma of unknown primary origin (MUPO) poses diagnostic and therapeutic challenges.
• MUPO accounts for approximately 4.8% of all melanoma cases.
• Understanding the characteristics and prognosis of MUPO is crucial for patient management.

Purpose of the Study:

• To analyze the clinical characteristics, presentation, and survival outcomes of patients with unknown primary melanoma.
• To compare the prognosis of MUPO with that of melanoma with a known primary site.
• To guide treatment strategies for patients diagnosed with MUPO.

Main Methods:

• Retrospective analysis of 124 patients diagnosed with unknown primary melanoma at Duke University Melanoma Clinic.
• Comparison of demographic data, clinical presentation (lymph node vs. hematogenous spread), and survival rates with control groups.
• Evaluation of prognostic factors influencing patient outcomes.

Main Results:

• Unknown primary melanoma represented 4.8% of the total melanoma population.
• The male-to-female ratio was 2.5:1, with an average age at diagnosis of 47.9 years.
• Regional lymph node metastasis was the most common presentation (64%); hematogenous spread indicated a worse prognosis.
• Survival rates for the unknown primary group were comparable to those with known primary melanomas.

Conclusions:

• Patients with unknown primary melanoma have similar survival outcomes to those with known primary sites.
• Surgical treatment approaches for unknown primary melanoma should mirror those used for known primary melanomas.
• Further research into the specific biology and optimal management of MUPO is warranted.